Sanofi halts a bronchiectasis trial for business reasons

A phase 2 study of SAR445399 in non-cystic fibrosis bronchiectasis was suspended, with strategic business reasons given rather than safety or efficacy.

Sanofi has suspended a phase 2 trial of SAR445399, a monoclonal antibody, in non-cystic fibrosis bronchiectasis. Fierce Biotech reports the reason given was strategic business reasons rather than a safety signal or a failure to show effect.

That distinction is the whole story, and it is why a halt like this belongs on a friction ledger even though nobody was harmed. A trial stopped for safety produces knowledge: the compound does not work, or it hurts people, and the field moves on better informed. A trial stopped for portfolio reasons produces nothing. The patients who enrolled carried the risk, the data are unlikely to be published in full, and the next sponsor to try the same target starts from where Sanofi started. Non-cystic fibrosis bronchiectasis has no approved disease-modifying therapy, which makes each abandoned shot expensive in a way that does not show up on any balance sheet.

We have to be straight about the limits of this card. Fierce Biotech blocked our fetcher today with a 403, so everything above the second paragraph comes from the outlet's own one-line summary and nothing more. We do not have the enrolment number, the trial identifier, the antibody's target or Sanofi's fuller statement. The card is scored down accordingly and will be worth revisiting if the company comments or the registry entry updates.

Source: Fierce Biotech